NeuroTherapia Raises $123 Million in Series B Financing

Breaking News:

NeuroTherapia Inc., a clinical-stage company focused on developing treatments for neurodegenerative diseases, has announced the closing of its Series B financing round, raising $123 million.

Key Points:

• The funding will support clinical development of NeuroTherapia's lead candidate NT-501, a potential treatment for frontotemporal dementia (FTD).
• NeuroTherapia is a portfolio company of Cleveland Clinic Innovations, the commercialization arm of the Cleveland Clinic.
• The financing round was led by New Enterprise Associates (NEA) and included participation from existing investors, including OrbiMed and Abingworth.